Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.

MLA

Varnier, Romain, et al. “Clinical Results of the EVESOR Trial, a Multiparameter Phase I Trial of Everolimus and Sorafenib Combination in Solid Tumors.” Cancer Chemotherapy and Pharmacology, vol. 91, no. 5, May 2023, pp. 361–73. EBSCOhost, https://doi.org/10.1007/s00280-023-04508-9.

APA

Varnier, R., Puszkiel, A., Tod, M., Calattini, S., Payen, L., Lopez, J., Guitton, J., Schwiertz, V., Fontaine, J., Peron, J., Maillet, D., Tartas, S., Bonnin, N., Colomban, O., Augu-Denechere, D., Freyer, G., & You, B. (2023). Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors. Cancer Chemotherapy and Pharmacology, 91(5), 361–373. https://doi.org/10.1007/s00280-023-04508-9

Chicago

Varnier, Romain, Alicja Puszkiel, Michel Tod, Sara Calattini, Lea Payen, Jonathan Lopez, Jérome Guitton, et al. 2023. “Clinical Results of the EVESOR Trial, a Multiparameter Phase I Trial of Everolimus and Sorafenib Combination in Solid Tumors.” Cancer Chemotherapy and Pharmacology 91 (5): 361–73. doi:10.1007/s00280-023-04508-9.